SMART LAB

Publication

Publication

Radiomics risk score may be a potential imaging biomarker for predicting survival in isocitrate dehydrogenase wild-type lower-grade gliomas
Journal
European Radiology
Vol
30
Page
6464–6474
Author
Chaejung Park, Kyunghwa Han, Hwiyoung Kim, Sung Soo Ahn, Yoon Seung Choi, Yae Won Park, Jong Hee Chang, Se Hoon Kim, Rajan Jain, and Seung-Koo Lee
Year
AI-powered Diagnosis
Date
Aug, 2020
File
Park2020_Article_RadiomicsRiskScoreMayBeAPotent.pdf (1.1M) 2회 다운로드 DATE : 2021-03-15 16:25:03
Objectives
Isocitrate dehydrogenase wild-type (IDHwt) lower-grade gliomas of histologic grades II and III follow heterogeneous clinical outcomes, which necessitates risk stratification. We aimed to evaluate whether radiomics from MRI would allow prediction of overall survival in patients with IDHwt lower-grade gliomas and to investigate the added prognostic value of radiomics over clinical features.

Methods
Preoperative MRIs of 117 patients with IDHwt lower-grade gliomas from January 2007 to February 2018 were retrospectively analyzed. The external validation cohort consisted of 33 patients from The Cancer Genome Atlas. A total of 182 radiomic features were extracted. Radiomics risk scores (RRSs) for overall survival were derived from the least absolute shrinkage and selection operator (LASSO) and elastic net. Multivariable Cox regression analyses, including clinical features and RRSs, were performed. The integrated areas under the receiver operating characteristic curves (iAUCs) from models with and without RRSs were calculated for comparisons. The prognostic value of RRS was assessed in the validation cohort.

Results
The RRS derived from LASSO and elastic net independently predicted survival with hazard ratios of 9.479 (95% confidence interval [CI], 3.220–27.847) and 6.148 (95% CI, 3.009–12.563), respectively. Those RRSs enhanced model performance for predicting overall survival (iAUC increased to 0.780–0.797 from 0.726), which was externally validated. The RRSs stratified IDHwt lower-grade gliomas in the validation cohort with significantly different survival.

Conclusion
Radiomics has the potential for noninvasive risk stratification and can improve prediction of overall survival in patients with IDHwt lower-grade gliomas when integrated with clinical features.